Key Documents

View All Documentation

SML2064

LBQ657

Name: LBQ657
Brand: SIGMA

≥97% (HPLC), neprilysin inhibitor, powder

Synonym(s):

(2R,4S)-5-(Biphenyl-4-yl)-4-((3-carboxypropionyl)amino)-2-methylpentanoic acid, Desethyl sacubitril, Sacubitrilat

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₅NO₅

CAS Number:

149709-44-4

Molecular Weight:

383.44

NACRES:

NA.77

UNSPSC Code:

12352200

MDL number:

MFCD00921225

Assay:

≥97% (HPLC)

Form:

powder

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

LBQ657, ≥97% (HPLC)

assay

≥97% (HPLC)

form

powder

optical activity

[α]/D -35 to -27°, c = 1 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

SMILES string

OC(CCC(N[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C[C@H](C(O)=O)C)=O)=O

InChI

1S/C22H25NO5/c1-15(22(27)28)13-19(23-20(24)11-12-21(25)26)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h2-10,15,19H,11-14H2,1H3,(H,23,24)(H,25,26)(H,27,28)/t15-,19+/m1/s1

InChI key

DOBNVUFHFMVMDB-BEFAXECRSA-N

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Biochem/physiol Actions

Inhibitor of neprilysin (neutral endopeptidase, NEP) formed by the action of esterases on its prodrug sacubitril (AHU377)

LBQ657 is the active metabolite of sacubitril. It is an inhibitor of the enkephalinase neprilysin (neutral endopeptidase, NEP) formed by the action of esterases on its prodrug sacubitril (AHU377), which is half of the heart failure combination drug Entresto, along with the angiotensin-receptor blocker Valsartan. LBQ657 prevents neprilysin′s degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides.

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H336,H372

pcodes

P260 - P264 - P271 - P304 + P340 + P312 - P314 - P403 + P233

Hazard Classifications

STOT RE 1 - STOT SE 3

target_organs

Bone,Kidney, Central nervous system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000525662

0000489469

0000489467

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.

Imad Hanna et al.

Xenobiotica; the fate of foreign compounds in biological systems, 48(3), 300-313 (2017-03-11)

1. The potential for drug-drug interactions of LCZ696 (a novel, crystalline complex comprising sacubitril and valsartan) was investigated in vitro. 2. Sacubitril was shown to be a highly permeable P-glycoprotein (P-gp) substrate and was hydrolyzed to the active anionic metabolite LBQ657 by

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Jessie Gu et al.

Journal of clinical pharmacology, 50(4), 401-414 (2009-11-26)

Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of

Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.

Sasha A S Kjeldsen et al.

Journal of the Endocrine Society, 5(9), bvab084-bvab084 (2021-08-03)

Inhibitors of the protease neprilysin (NEP) are used for treating heart failure, but are also linked to improvements in metabolism. NEP may cleave proglucagon-derived peptides, including the glucose and amino acid (AA)-regulating hormone glucagon. Studies investigating NEP inhibition on glucagon

Long-term neprilysin inhibition - implications for ARNIs.

Duncan J Campbell

Nature reviews. Cardiology, 14(3), 171-186 (2016-12-16)

Neprilysin has a major role in both the generation and degradation of bioactive peptides. LCZ696 (valsartan/sacubitril, Entresto), the first of the new ARNI (dual-acting angiotensin-receptor-neprilysin inhibitor) drug class, contains equimolar amounts of valsartan, an angiotensin-receptor blocker, and sacubitril, a prodrug

Global Trade Item Number

SKU	GTIN
SML2064-5MG	04061832944739
SML2064-25MG	04061832944722

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service